More results from the RECOVERY trial - Hydroxychloroquine:

Among patients hospitalised with COVID-19, hydroxychloroquine (HCQ) did not improve 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death

nejm.org/doi/full/10.10… Image
1561 patients were randomised to HCQ + usual care
3155 patients were randomised to usual care alone
in the largest randomised trial of HCQ for treatment of COVID Image
No evidence of benefit of HCQ on any of the pre-specified endpoints. Image
No evidence of benefit of HCQ in any of the pre-specified subgroups of patients Image
I have been asked about the effect of HCQ in the 91% of patients with a positive test for SARS-CoV-2 (coronavirus).

No evidence of benefit in those patients either: Image
The WHO SOLIDARITY trial has subsequently announced similar results and has discontinued enroling patients to the HCQ arm of that study:
who.int/news-room/deta…
Note: we did not study the use of HCQ for prophylaxis (prevention) or for treatment of patients outside hospital with milder forms of COVID.
Please remember:
- like every drug we study, we hoped it would work
- like every drug we study, we couldn't be sure it would work
- like every drug we study, we did the trial to find out

Now we know the answer in hospitalised pts
- HCQ does not work

Disappointing but important
The RECOVERY trial has now answered 3 questions for hospitalised COVID pts:
- HCQ is not effective
- Lopinavir is not effective
- Dexamethasone reduces mortality for patients on oxygen or mechanical ventilators

All 3 results have changed medical practice & benefited patients
We push on with the study of 4 further treatments. Same rationale - we think they might work, we need to know if they do work, how well, & for whom:
- azithromycin
- tocilizumab
- convalescent plasma
- REGN-COV2 monoclonal neutralising antibodies

Answer to follow.
And as ever: Huge thanks to absolutely everyone involved - funders, researchers, data scientists, doctors, nurses, pharmacists, across the whole UK.

But most of all thanks to the amazing & ongoing contribution of the more than 13,000 patients who have taken part in RECOVERY.
There is a full list of >3,000 collaborators, contributors, funders & supporting organizations in the Appendix. Thank you

Team science - bringing clinical trials to the bedside in a shared effort to find effective treatments for future patients with COVID
nejm.org/doi/suppl/10.1…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Martin Landray

Martin Landray Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MartinLandray

7 Oct
Great summary of treatments for hospitalised patients with COVID-19 @rupert_pearse

threadreaderapp.com/thread/1312699…
My take on this:

Dexamethasone improves survival.
Remdesivir shortens time to recovery.
Hydroxychloroquine & lopinavir are ineffective.

** we know because the clinical trials have been done**
Tocilizumab, Convalescent plasma, and neutralising antibodies look promising

** we will know because we are doing the clinical trials**
Read 5 tweets
6 Oct
Latest paper from RECOVERY trial:

In patients admitted to hospital with COVID-19, lopinavir–ritonavir did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

thelancet.com/journals/lance…
Lopinavir-ritonavir is an HIV treatment that was widely recommended and used for #COVID19. The RECOVERY trial has shown it does not work - so doctors no longer use it.

That’s why we do trials - to separate out drugs we think might work from drugs we know do work.
As always, huge thanks to all involved including funders (@UKRI_News @NIHRresearch), colleagues (@OxfordBRC @hdruk @Oxford_NDPH @NDMOxford), the NHS (@NHSEngland @NHSDigital) and the thousands of medical staff across the whole UK.

But most especially to our amazing patients.
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!